New York, March 2, 2026, 14:32 (EST) — Trading in the regular session.
Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.
This is significant: Lilly’s stock is packed with bets on its weight-loss and diabetes treatments, so expectations don’t leave much room for error. Even minor changes in demand, supply, or pricing can send shares sharply higher or lower, given their growth-heavy valuation.
Health stocks lost ground Monday, dragging on the sector. The Health Care Select Sector SPDR, an ETF tracking major U.S. healthcare firms, dropped roughly 0.9%. That move stood out as the SPDR S&P 500 ETF ticked up. Novo Nordisk’s U.S. shares barely moved.
Innovent Biologics announced that China’s drug regulator cleared Jaypirca (pirtobrutinib) for a new indication: treating chronic lymphocytic leukemia or small lymphocytic lymphoma in patients who’ve already tried at least one therapy with a BTK inhibitor, a class that targets a critical B-cell protein. Data from a late-stage trial showed Jaypirca held off disease progression for 14.0 months, compared with 8.7 months on previous standard regimens. Li Wang, an executive at Lilly, called the approval an “important milestone” for those who need alternatives after BTK therapies. PR Newswire
This approval slots into Lilly’s wider oncology lineup, though it doesn’t answer lingering questions over the company’s main growth story. The spotlight from investors remains firmly on Lilly’s GLP-1 portfolio, drugs designed to imitate a gut hormone for appetite suppression and lower blood sugar. The bigger focus: speed of access expansion and how Lilly manages to hold the line on net prices.
Eli Lilly disclosed on Feb. 12 that it has stockpiled $1.5 billion worth of pre-launch inventory for its experimental oral GLP-1 pill, orforglipron, in advance of a possible FDA green light expected in April. That stash jumped from around $550 million just a year ago, underscoring the company’s readiness to move quickly if regulators give the go-ahead.
The pill doesn’t come without drawbacks. On Feb. 26, data showed orforglipron outperformed Novo’s oral semaglutide (Rybelsus) for blood sugar control and weight loss in direct comparison, but higher rates of gastrointestinal side effects and increased treatment discontinuation at the top dose raised concerns.
Traders have an eye on Eli Lilly’s CFO Lucas Montarce, set to take the stage at TD Cowen’s annual health-care conference at 3:10 p.m. EST.
Lilly’s first-quarter earnings call lands April 30—the next major date circled for investors. Until then, the focus stays on any updates about obesity-drug supply, pricing clarity, and when the FDA might finish reviewing orforglipron in the U.S.
